文献速递骨质疏松与钙磷/甲状旁腺

地舒单抗治疗原发性甲状旁腺功能亢进症高钙血症的疗效与安全性:一项回顾性研究

The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该回顾性研究比较地舒单抗与唑来膦酸治疗原发性甲状旁腺功能亢进症(PHPT)相关中重度高钙血症的疗效与安全性。地舒单抗组(60或120 mg)与校正血清钙匹配的唑来膦酸组(4 mg)各29例,两组校正血清钙均显著下降且降幅相似;地舒单抗组完全缓解时间较长但缓解持续时间较长,低钙血症发生2例。

要点

  • 地舒单抗组校正血清钙从3.37±0.37 mmol/L降至2.64±0.33 mmol/L(P<.01),唑来膦酸组从3.41±0.32 mmol/L降至2.57±0.23 mmol/L(P<.01)。
  • 地舒单抗组82.8%(24/29)校正血清钙降至3.0 mmol/L以下,72.4%(21/29)达完全缓解(校正血清钙<2.7 mmol/L),与唑来膦酸组相当。
  • 唑来膦酸组完全缓解时间更短(3.0 vs 7.0天,P<.01),地舒单抗组缓解持续时间更长(19.0 vs 13.0天,P=.02)。

核心结论

  • 单次60 mg地舒单抗可有效降低PHPT中重度高钙血症患者的血清钙水平,中位维持疗效近3周,未发生严重不良事件。

研究设计与样本

  • 回顾性研究,收集29例接受地舒单抗(60或120 mg)治疗的PHPT中重度高钙血症(校正血清钙≥3.0 mmol/L)患者数据,并与校正血清钙匹配的29例接受唑来膦酸(4 mg)治疗的PHPT患者比较。
  • 主要疗效结局为校正血清钙变化(ΔCa),次要结局包括缓解比例、缓解时间和缓解持续时间,同时收集安全性数据。

主要发现

  • 两组校正血清钙均显著下降:地舒单抗组从3.37±0.37 mmol/L降至2.64±0.33 mmol/L(P<.01),唑来膦酸组从3.41±0.32 mmol/L降至2.57±0.23 mmol/L(P<.01),ΔCa相似。
  • 地舒单抗组82.8%(24/29)缓解(校正血清钙<3.0 mmol/L),72.4%(21/29)达完全缓解(校正血清钙<2.7 mmol/L),与唑来膦酸组相当。
  • 完全缓解时间唑来膦酸组更短(3.0 vs 7.0天,P<.01),地舒单抗组缓解持续时间更长(19.0 vs 13.0天,P=.02)。
  • 地舒单抗组低钙血症发生率为6.9%(2/29,两例均为慢性肾脏病3b期),唑来膦酸组无低钙血症发生。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Denosumab is approved for treating hypercalcemia of malignancy, but data on its efficacy for hypercalcemia related to primary hyperparathyroidism (PHPT) are limited. OBJECTIVE: To compare the efficacy and safety of denosumab with zoledronic acid in PHPT-related hypercalcemia. METHODS: We retrospectively collected data from 29 PHPT patients with moderate/severe hypercalcemia (corrected serum calcium [CSC] ≥ 3.0 mmol/L) treated with denosumab (60 or 120 mg; Dmab group) and CSC-matched 29 PHPT patients treated with zoledronic acid (4 mg; ZA group). The primary efficacy outcome was the change of CSC (ΔCa), while secondary outcomes included the response proportion, time to response, and duration of response. Safety data were also collected. RESULTS: Both groups showed significant reductions in CSC levels (Dmab: 3.37 ± 0.37 mmol/L to 2.64 ± 0.33 mmol/L, P < .01; ZA: 3.41 ± 0.32 mmol/L to 2.57 ± 0.23 mmol/L, P < .01), with similar ΔCa. In the Dmab group, 82.8% (24/29) responded with CSC levels below 3.0 mmol/L, and 72.4% (21/29) achieved complete response (CR, serum CSC less than 2.7 mmol/L), comparable to the ZA group. The time to CR was shorter for ZA (3.0 vs 7.0 days, P < .01), while Dmab had a longer duration of response (19.0 vs 13.0 days, P = .02). Hypocalcemia occurred in 6.9% (2/29, both with chronic kidney disease stage 3b) of Dmab patients, while none in the ZA group. CONCLUSION: A single 60-mg dose of denosumab effectively reduces serum calcium levels in PHPT patients with moderate/severe hypercalcemia, at least maintaining efficacy for a median of nearly 3 weeks without serious adverse events.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Song A, Chen Y, Chen R, et al. The Efficacy and Safety of Denosumab for Treating Hypercalcemia in Primary Hyperparathyroidism: A Retrospective Study. J Clin Endocrinol Metab. 2025. PMID: 40037575. doi:10.1210/clinem/dgaf107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。